ANXA1

Across TCGA pan-cancer cohorts, ANXA1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANXA1 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher ANXA1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ANXA1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SKCM, BRCA, and CESC are the cancer types where ANXA1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	1.000	0.537	.003	28	view →
BRCA	OS	Median	III,IV	0.200	0.833	<.001	14	view →
CESC	OS	Median	II,III,IV	0.203	0.759	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ANXA1–SKCM (DFS)

Open the SKCM breakdown →